Melanotan II vs Semaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan II
Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.
Full details →Semaglutide
Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030.
Full details →Side-by-Side Comparison
| Aspect | Melanotan II | Semaglutide |
|---|---|---|
| Dose Range | 250 mcg–1 mg | 250 mcg–2.4 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 1–2 weeks | 16–52 weeks |
| Route | subcutaneous | subcutaneous or oral |
| Mechanism | Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning. | Semaglutide binds to and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract. This triggers multiple downstream effects: (1) glucose-dependent insulin secretion from pancreatic beta cells, (2) suppression of glucagon release from alpha cells, (3) delayed gastric emptying, slowing nutrient absorption, (4) central appetite suppression via hypothalamic GLP-1 receptors, reducing hunger and increasing satiety. The peptide features a C-18 fatty diacid moiety attached via a linker to Lys26, enabling non-covalent albumin binding that protects against DPP-4 degradation and renal clearance. |
| Typical Dosage | Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance. | For weight management (Wegovy): start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly. Each escalation lasts 4 weeks. Maintenance dose is 2.4 mg weekly. For type 2 diabetes (Ozempic): start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg. May increase to 1 mg, then 2 mg if additional glycemic control is needed. Oral semaglutide (Rybelsus): 3 mg daily for 30 days, then 7 mg daily. May increase to 14 mg daily. Oral Wegovy: 3 mg daily for 4 weeks, escalate to 7 mg, 14 mg, and 25 mg daily. Take on empty stomach with no more than 4 oz of water, 30 minutes before food. |
| Administration | Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability. | Injectable: subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Store pens refrigerated (36-46°F) before first use; after first use, store at room temperature or refrigerated for up to 56 days. Oral: take on an empty stomach with a sip of plain water (no more than 4 oz). Wait at least 30 minutes before eating, drinking, or taking other oral medications. Do not split, crush, or chew tablets. |
| Side Effects | Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening. | Very common (>10%): nausea (up to 44%), diarrhea, vomiting, constipation, abdominal pain. These are typically mild-to-moderate and decrease over time with dose escalation. Common (1-10%): headache, fatigue, dyspepsia, dizziness, bloating, flatulence, GERD, gastroenteritis. Notable: 'Ozempic face' (facial volume loss due to rapid weight loss), hair loss (telogen effluvium, reported in 25-33% of users in some studies), injection site reactions. |
| Best For |
Key Differences
Unique to Melanotan II:
Unique to Semaglutide:
Key Studies
Melanotan II
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
International journal of oral and maxillofacial surgery, 2025
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.
Dermatology (Basel, Switzerland), 2021
- Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice.
Experimental physiology, 2021
Semaglutide
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
The New England journal of medicine, 2025
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.
JAMA ophthalmology, 2025
Ready to Learn More?
Looking for trusted sources?